SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Goldman Sachs Buy upgrade, tied to Palantirs sovereign-AI and customized-software opportunities, is a key catalyst as shares break to a new high. Bulls are celebrating the momentum and speculating about a short squeeze, while skeptics argue the valuation is stretched and warn of a pullback.

T-Mobile US, Inc. engages in the provision of wireless communications services under the T-Mobile and MetroPCS brands. It offers postpaid and prepaid wireless voice, messaging and data services, and wholesale wireless services. The company was founded in 1994 and is headquartered in Bellevue, WA.

T-Mobile US Inc

SpaceXs planned acquisition of low-band spectrum for Starlink Mobile has intensified fears that it could eventually compete with established wireless carriers, contributing to a sharp selloff in T-Mobile shares. Traders are divided between concerns about long-term pressure on carriers pricing and market share and the view that building a competitive network will take years, making the drop an overreaction.

Nasdaq, Inc. is a holding company, which engages in trading, clearing, exchange technology, regulatory, securities listing, information, and public and private company services. It operates through the following segments: Capital Access Platforms, Financial Technology, and Market Services. The Capital Access Platforms segment delivers liquidity, transparency, and integrity to the corporate issuer and investment community by empowering clients to effectively navigate the capital markets, achieve their sustainability goals, and drive governance excellence. The Financial Technology segment offers platforms that improve the liquidity, transparency, and integrity of the global economy by architecting and operating the markets. The Market Services segment includes equity derivative trading and clearing, cash equity trading, fixed income, currency, and commodities trading. The company was founded by Gordon S. Macklin in 1971 and is headquartered in New York, NY.

Nasdaq Inc

Discussion is fragmented, with traders debating NDAQs technical direction and broader market moves. A recurring company-specific topic is Nasdaqs push toward near-continuous trading and tokenized equities, viewed by some as a potential growth opportunity and by others with concern about the risks.

Verizon Communications, Inc. is a holding company, which engages in the provision of communications, information, and entertainment products and services. It operates through the following business segments: Consumer and Business. The Consumer segment provides consumer-focused wireless and wire line communications services and products. The Business segment offers wireless and wireline communications services and products, including FWA broadband, data, video and conferencing services, corporate networking solutions, security and managed network services, local and long-distance voice services, and network access to deliver various IoT services and products. The company was founded in 1983 and is headquartered in New York, NY.

Verizon Communications Inc

Verizon Communications Inc.

Verizon shares sold off amid concerns that SpaceXs low-band spectrum acquisition could help Starlink Mobile compete with established wireless carriers. Traders are divided between viewing the move as a long-term threat and calling the selloff premature or overdone given the infrastructure and time needed to build a competing network; some see the drop as a buying opportunity.

Amarin Corp. Plc is a pharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. It focuses on the development and commercialization of Vascepa capsules. The company was founded by Geoffrey William Guy on March 1, 1989 and is headquartered in Dublin, Ireland.

Amarin Corp - ADR

AMRN is drawing attention amid a steep slide toward 52-week lows, prompting frustration over management and debate about the companys value despite its cash position and international growth. Traders are also focused on the pending Phase 3 EMT-2 results and LR-EtEPA patent, with bullish speculation about their potential weighed against uncertainty about the data, patent prospects, and how either could translate into commercial value.

Air Canada engages in the provision of airline transportation services. Its services cover full-service airline, scheduled passenger and cargo services, serving more than two hundred airports on six continents. It operates through the following geographical segments: Canada, U.S. Transborder, Atlantic, Pacific, and Other. The company was founded on April 11, 1936 and is headquartered in Saint-Laurent, Canada.

Air Canada Inc. - Ordinary Shares (Voting and Variable Voting)

Air Canada Inc.

Air Canadas sharp selloff has traders debating whether shares left over from its substantial issuer bid are being sold into the market and whether short pressure is driving the decline; bulls point to possible further buybacks, while others cite elevated fuel costs as a risk to margins.

StarkNet is a permissionless decentralized Layer 2 (L2) validity rollup, built to allow Ethereum to scale via cryptographic protocols called STARKs, without compromising Ethereum’s core principles of decentralization, transparency, inclusivity and security. The StarkNet Token is needed to operate the ecosystem, maintain and secure it, decide on its values and strategic goals, and direct its evolution. This token will be required for (i) governance, (ii) payment of transaction fees on StarkNet, and (iii) participation in StarkNet’s consensus mechanism.

Starknet

STRK is drawing attention for its rally and Starknets privacy and Bitcoin DeFi push, particularly shielded strkBTC and STRK20, alongside its post-quantum security narrative. Traders are broadly enthusiastic about the technology, though some remain concerned about token unlocks and dilution.

Tidal Trust II - YieldMax MSTR Option Income Strategy ETF

YieldMax MSTR Option Income Strategy ETF

MSTY is drawing attention for its weekly distributions and price swings tied to Bitcoin and MSTR. Income-focused holders welcome the cash flow and see potential for recovery if the underlying strengthens, while skeptics point to NAV erosion and fluctuating or declining payouts as risks.

Datadog, Inc. engages in the development of a monitoring and analytics platform for developers, information technology operations teams and business users. Its platform integrates and automates infrastructure monitoring, application performance monitoring and log management to provide real-time observability of its customers' entire technology stack. The company was founded by Olivier Pomel and Alexis Lê-Quôc on June 4, 2010 and is headquartered in New York, NY.

Datadog Inc - Ordinary Shares - Class A

Datadog Inc

Datadog is drawing attention after a sharp breakout to fresh highs alongside strength in software stocks. Bulls point to momentum and demand for AI observability, while bears warn that the valuation is stretched and see risk of a technical reversal.

KLA Corp. engages in the supply of process control and yield management solutions for the semiconductor and related nano-electronics industries. The company operates through the following segments: Semiconductor Process Control, Specialty Semiconductor Process, and PCB, Display and Component Inspection. The Semiconductor Process Control segment provides a comprehensive portfolio of inspection, metrology and data analytics products and related services. The Specialty Semiconductor Process segment develops and sells advanced vacuum deposition and etching process tools. The PCB, Display and Component Inspection segment enables electronic device manufacturers to inspect, test and measure PCBs, flat panel displays and ICs to verify their quality. Its products include manufactured chips, reticle, packaging, surface profilers, nanochemical testers, KT pro equipment, and compound semiconductors. The company was founded on July 9, 1975 and is headquartered in Milpitas, CA.

KLA Corp.

KLAs earnings beat estimates, but the stock sold off as traders said results and guidance fell short of elevated expectations, alongside weakness across semiconductor-equipment shares and concerns about China exposure and competition. The community is split between viewing the decline as an overreaction and buying the dip, and expecting further downside.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Will Camzyos Growth Keep Driving BMY's Cardiovascular Portfolio?

Bristol Myers' Camzyos gains a broader FDA label and strong sales growth, while emerging competitors and pipeline setbacks shape its cardiovascular outlook.

Here's How Much You Would Have Made Owning Cytokinetics Stock In The Last 15 Years

Cytokinetics (NASDAQ:CYTK) has outperformed the market over the past 15 years by 2.64% on an annualized basis producing an average annual return of 15.99%. Currently, Cytokinetics has a market capitalization of $9.70read more...

If You Invested $1000 In Cytokinetics Stock 10 Years Ago, You Would Have This Much Today

Cytokinetics (NASDAQ:CYTK) has outperformed the market over the past 10 years by 10.3% on an annualized basis producing an average annual return of 23.89%. Currently, Cytokinetics has a market capitalization of $10.16read more...

Will Camzyos' Long-Term Benefits Strengthen BMY's Growth Outlook? 

Bristol Myers??? Camzyos delivers durable five-year benefits, rising sales and potential adolescent label expansion.

Can CYTK's Aficamten Strengthen Its HCM Growth Prospects?

Cytokinetics' aficamten shows added benefits in HCM studies, strengthening its potential in non-obstructive and obstructive disease.

Cytokinetics Investors Weigh Safety Data From Pivotal Trial

Cytokinetics reports Phase 3 results for aficamten in treating hypertrophic cardiomyopathy, targeting a Q4 FDA submission.read more...

If You Invested $100 In Cytokinetics Stock 10 Years Ago, You Would Have This Much Today

Cytokinetics (NASDAQ:CYTK) has outperformed the market over the past 10 years by 7.78% on an annualized basis producing an average annual return of 21.28%. Currently, Cytokinetics has a market capitalization of $10.34read more...

Can Camzyos' Growth Offset Bristol Myers' Patent Pressures?

BMY's Camzyos gains momentum as an adolescent expansion nears an FDA decision, while rivals advance competing heart drugs.

Insider Transaction: Cytokinetics CEO Robert Blum Sells 7,500 Shares for $575,700

Key PointsThe transaction involved the disposal of 7,500 shares...

Cytokinetics Gains 20.5% YTD: Buy, Sell or Hold the Stock? 

Myqorzo's early launch momentum and global expansion could boost Cytokinetics, while pipeline progress may widen its growth opportunity.

Cytokinetics, Inc. is a biopharmaceutical company, which is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. The firm is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. Its clinical-stage drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator, CK-136, a novel cardiac troponin activator, reldesemtiv, a novel fast skeletal muscle troponin activator, aficamten, a novel cardiac myosin inhibitor, and CK-3772271, a novel cardiac myosin inhibitor. The company was founded by Ronald D. Vale, Lawrence S. B. Goldstein, James H. Sabry, and James A. Spudich in 1997 and is headquartered in South San Francisco, CA.

Cytokinetics Inc

CYTK Stock Jumped To Over 2-Year Highs On HCM Trial Outcome – So, Why Are Analysts Bullish On Edgewise Therapeutics?

Equity

Neutral Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Stocktwits

Stocktwits Polls

$CYTK I seen a Bezinga wire article Friday that said wholesales are tracking double this quarter vs last .. " Cytokinetics, Incorporated’s (NASDAQ:CYTK) MYQORZO wholesale sales are tracking toward roughly $18 million for the third quarter, versus $8.9 million for the entire second quarter, according to B. Riley."  I am not sure how whole sale relates to net product revenue but if we get 100% more sales that's going to be great.

Chris Daniel

$CYTK  Why is the CEO and his team selling stock. Do they know something and not disclosing. Their selling is just non-stop. They have a good product to market. The management is sending wrong signals by selling the stock. Marketing is working to sell and product and selling the stock damages company reputation.  
 
On a serious note, is their something that CYTK not disclosing. This could become a possible SEC investigation if something is disclosed down a year.  
 
Or do they know something about the lawsuit with BMY. Is something fishy ?

Feed

News

Sentiment

Earnings

Fundamentals

Info

CYTK Cytokinetics Inc

Fundamentals

Latest CYTK News